WO1999047131A2 - Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor - Google Patents

Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor Download PDF

Info

Publication number
WO1999047131A2
WO1999047131A2 PCT/GB1999/000778 GB9900778W WO9947131A2 WO 1999047131 A2 WO1999047131 A2 WO 1999047131A2 GB 9900778 W GB9900778 W GB 9900778W WO 9947131 A2 WO9947131 A2 WO 9947131A2
Authority
WO
WIPO (PCT)
Prior art keywords
inverse agonist
combination
gabaa
acetylcholinesterase inhibitor
receptor subtype
Prior art date
Application number
PCT/GB1999/000778
Other languages
French (fr)
Other versions
WO1999047131A3 (en
Inventor
Gerard Raphael Dawson
Original Assignee
Merck Sharp & Dohme Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Limited filed Critical Merck Sharp & Dohme Limited
Priority to JP2000536371A priority Critical patent/JP2002506815A/en
Priority to AU28464/99A priority patent/AU753077B2/en
Priority to EP99909095A priority patent/EP1061952A2/en
Priority to CA002323618A priority patent/CA2323618A1/en
Publication of WO1999047131A2 publication Critical patent/WO1999047131A2/en
Publication of WO1999047131A3 publication Critical patent/WO1999047131A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention relates to a combination of an acetylcholinesterase inhibitor and an inverse agonist of the GABAA s receptor subtype, and the use of the combination in treating neurodegenerative conditions such as Alzheimer's Disease.
  • Alzheimer's Disease is a poorly understood neurodegenerative condition mainly affecting the elderly but also younger people who are generally genetically predispositioned to it.
  • One postulated method of treatment comprises the administration of acetylcholinesterase inhibitors which act on the cholinergic system.
  • this method suffers from the disadvantages that these compounds induce a range of side-effects including diarrhoea, salivation and nausea.
  • the present invention provides a new and surprisingly effective synergistic combination of an acetylcholinesterase inhibitor and an inverse agonist of the GABAA ⁇ g receptor subtype for separate, sequential or simultaneous administration.
  • the present invention provides a greater than expected improvement in the condition of subjects suffering from a neurodegenerative with an associated cognitive deficit, such as Alzheimer's Disease or Parkinson's disease, or from a cognitive deficit which may arise from a normal process such as aging or from an abnormal process such as injury, than would be expected from administration of the active ingredients alone.
  • the combination allows for a lower overall dose of each of the active ingredients to be administered thus reducing side effects and decreasing any reduction in the effectiveness of each of the active ingredients over time.
  • Acetylcholinesterase inhibitors which may be used include any which are known to the skilled person. Examples are physostigmine, neostigmine, edrophonium and its chloride, pyridostigmine and its bromide, eptastigmine.and its tartrate, galanthamine and its hydrochloride and hydrobromide, metrifonate, tacrine and its hydrochloride, eseridine and its salicylate, suronacrine and its maleate, velnacrine and its maleate, amiridine and its hydrochloride, 7- methoxy tacrine, SM-10888 and its citrate, phenserine and its tartrate, ENA-713, donepezil and its hydrochloride, TAK-147, CP-118954, huperzine A and zifrosilone.
  • any inverse agonist of the GABAA as receptor subtype may be used which fulfills the criteria of WO-A-9625948.
  • the inverse agonist may be either binding selective for the 0:5 subtype or functionally selective, or both.
  • the inverse agonist is preferably an antagonist, or has insignificant agonist or inverse agonist properties at the other GABAA receptor subtypes when measured in oocytes as described in WO-A-9625948.
  • the inverse agonist preferably has a functional efficacy at the g receptor subunit of less than -20% and functional efficacies at the ⁇ i, ⁇ .2, and 0:3 receptor subunits of between -20 and +20%.
  • functional efficacy is meant the percentage modulation of the EC20 response produced by GABA, upon coadministration of the inverse agonist, in oocytes expressing GABAA receptor channels containing the ⁇ receptor subunit under test. Details of this measurement are given in WO-A-9625948.
  • the inverse agonist preferably binds selectively to GABAA receptors containing the as subunit 10, 25 and particularly 50 times compared to GABAA receptors subunits containing the ⁇ i, 0:2 or 0:3 subunits. Preferably this binding selectivity is shown over all these subunits.
  • a preferred class of inverse agonists which are disclosed in WO-A-9850385, are of formula I:
  • R 1 is hydrogen, halogen or CN or a group C ⁇ -4alkyl, C2-4alkenyl, C2-4alkynyl, Ci. alkoxy, C2-4alkenyloxy or C 2 -4alkynyloxy, each of which groups is unsubstituted or substituted with one or two halogen atoms or with a pyridyl or phenyl ring each of which rings may be unsubstituted or independently substituted by one or two halogen atoms or nitro, cyano, amino, methyl or CF3 groups;
  • R 2 is hydrogen, halogen or CN or a group C ⁇ -4alkyl, C2- 4 alkenyl,
  • L is 0, S or NR n where R n is H, Cj- ⁇ alkyl or C3-6cycloalkyl;
  • X is a 5-membered heteroaromatic ring containing 1, 2, 3 or 4 heteroatoms independently chosen from oxygen, nitrogen and sulphur, at most one of the heteroatoms being oxygen or sulphur, or a 6-membered heteroaromatic ring containing 1, 2 or 3 nitrogen atoms, the 5- or 6-membered heteroaromatic ring being optionally fused to a benzene ring and the heteroaromatic ring being optionally substituted by R x and/or R ' and/or R*, where R x is halogen, R 3 , OR*, OCOR 3 , NR R 5 , NR COR 5 , tri(C 1 - 6 alkyl)silylC 1 -6alkoxyC 1 - alkyl ) CN or R 9 , is halogen, R 3 , OR 3 , OCOR 3 , NR 4 R 5 , NR 4 COR 5 or CN and R* is R 3 , OR 3 or OCOR
  • Y is optionally branched Cj. 4 alkylidene optionally substituted by an oxo group or Y is a group (CH 2 )jO wherein the oxygen atom is nearest the group X and j is 2, 3 or 4;
  • Z is a 5-membered heteroaromatic ring containing 1, 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulphur, at most one of the heteroatoms being oxygen or sulphur and providing that when two of the heteroatoms are nitrogen an oxygen or sulphur atom is also present and that when one of the atoms is oxygen or sulphur then at least one nitrogen atom is present, or a 6-membered heteroaromatic ring containing 2 or 3 nitrogen atoms, Z being optionally substituted by R v and/or R w , where R v is halogen, R G , NR 7 R 8 , NR 7 COR 8 , CN, furyl, thienyl, phenyl, benzyl, pyridyl or a 5-membered heteroaromatic ring containing at least one nitrogen atom and optionally 1, 2 or 3 other heteroatoms independently selected from oxygen, nitrogen and sulphur, at most one of the other heteroatoms being oxygen or
  • R G is Ci- ⁇ alkyl, C2-6alkenyl, C2-6alkynyl, C3-Gcycloalkyl, hydroxyd-calkyl, Ci-calkoxy, C2 c,alkenyloxy, C2-6alkynyloxy, CH2F or CF3; and R 7 and R 8 are each independently hydrogen, Ci-ealkyl, C2- G alkenyl, C2-6alkynyl, C3-Gcycloalkyl or CF3 or R 7 and R 8 , together with the nitrogen atom to which they are attached, form a 4-7 membered heteroaliphatic ring containing the nitrogen atom as the sole heteroatom; or a pharmaceutically acceptable salt thereof.
  • d-Galkyl includes methyl and ethyl groups, and straight-chained and branched propyl, butyl, pentyl and hexyl groups. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and t-butyl. Derived expressions such as “C2-4alkenyl”, “C 2 -6alkeny_”, “hydroxyCi-calkyl", “C 2 -4alkyl” and "C 2 . 6 alkyny_” are to be construed in an analogous manner.
  • C3-Gcycloalkyl as used herein includes cyclic propyl, butyl, pentyl and hexyl groups such as cyclopropyl and cyclohexyl.
  • Suitable 5- and 6-membered heteroaromatic rings include pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, oxadiazolyl and thiadiazolyl groups.
  • a suitable 5-membered heteroaromatic ring containing four nitrogen atoms is tetrazolyl.
  • Suitable 6-membered heteroaromatic rings containing three nitrogen atoms include 1,2,4-triazine and 1,3,5-triazine.
  • halogen as used herein includes fluorine, chlorine, bromine and iodine, of which fluorine and chlorine are preferred.
  • Ci- ⁇ alkoxy includes methoxy and ethoxy groups, and straight-chained, branched and cyclic propoxy, butoxy, pentoxy and hexoxy groups, including cyclopropylmethoxy. Derived expressions such as “C2-6alkenyloxy”, “C2-6alkynyloxy”, “C 1 - 4 alkoxy”,
  • the present invention also provides a pharmaceutical composition comprising an acetylcholinesterase inhibitor, an inverse agonist of the GABAA 0.5 receptor subtype and a pharmaceutically acceptable carrier.
  • a kit of parts comprising a first pharmaceutical composition comprising an acetylcholinesterase inhibitor and a first pharmaceutically acceptable carrier and a second pharmaceutical composition comprising an inverse agonist of the GABAA 0.5 receptor subtype and a second pharmaceutically acceptable carrier for simultaneous, sequential or separate administration.
  • a combination of an acetylcholinesterase inhibitor and an inverse agonist of the GABAA 0.5 receptor subtype for use in a method of treatment of the human body, particularly for the treatment of a neurodegenerative disorder with associated cognitive deficit such as Alzheimer's Disease or Parkinson's disease, or of a cognitive deficit arising from a normal process such as aging or of an abnormal process such as injury.
  • the combination is particularly beneficial in the treatment of Alzheimer's Disease.
  • a combination of an acetylcholinesterase inhibitor and an inverse agonist of the GABAA s receptor subtype in the manufacture of a medicament for the treatment of a neurodegenerative disorder such as Alzheimer's Disease or Parkinson's disease, or of a cognitive deficit arising from a normal process such as aging or of an abnormal process such as injury.
  • the treatment of Alzheimer's Disease is particularly preferred.
  • a method of treatment of a subject suffering from a neurodegenerative disorder such as Alzheimer's Disease or Parkinson's disease, or a cognitive deficit arising from a normal process such as aging or an abnormal process such as injury, which comprises administering to that subject a therapeutically effective amount of a combination of an acetylcholinesterase inhibitor and an inverse agonist of the GABAA 0.5 receptor subtype.
  • a neurodegenerative disorder such as Alzheimer's Disease or Parkinson's disease
  • a cognitive deficit arising from a normal process such as aging or an abnormal process such as injury
  • the treatment of Alzheimer's Disease is particularly preferred.
  • compositions of the present invention are preferably in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, transdermal patches, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation.
  • a pharmaceutical carrier e.g.
  • This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of each active ingredient of the present invention.
  • Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of each active ingredient.
  • the tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
  • liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
  • Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
  • a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.01 to 100 mg/kg per day, and especially about 0.01 to 5 mg/kg of body weight per day of each active ingredient.
  • the compounds may be administered on a regimen of 1 to 4 times per day. In some cases, however, dosage outside these limits may be used.
  • the synergistic effect of the combination of the present invention can be shown, for example, by comparing the combined dosage of the combination with dosages of the same amount of each of the active ingredients separately on subjects using the Mini-Mental State Examination (MMSE) as described in Folstein and Folstein J. Psychiat. Res., 1975, 12, 189-198 or a variant thereof as discussed in Tombaugh and Mclntyre, JAGS, 1992, 40, 922-935.
  • MMSE Mini-Mental State Examination

Abstract

The present invention relates to a combination of an acetylcholinesterase inhibitor and an inverse agonist of the GABAA α5 receptor subtype, and the use of the combination in treating neurodegenerative conditions such as Alzheimer's Disease.

Description

COMBINATION OF A GABA-A ALPHA 5 INVERSE AGONIST AND AN ACETYLCHOLINESTERASE INHIBITOR
The present invention relates to a combination of an acetylcholinesterase inhibitor and an inverse agonist of the GABAA s receptor subtype, and the use of the combination in treating neurodegenerative conditions such as Alzheimer's Disease.
Alzheimer's Disease is a poorly understood neurodegenerative condition mainly affecting the elderly but also younger people who are generally genetically predispositioned to it.
One postulated method of treatment comprises the administration of acetylcholinesterase inhibitors which act on the cholinergic system. However this method suffers from the disadvantages that these compounds induce a range of side-effects including diarrhoea, salivation and nausea.
The present invention provides a new and surprisingly effective synergistic combination of an acetylcholinesterase inhibitor and an inverse agonist of the GABAA αg receptor subtype for separate, sequential or simultaneous administration. The present invention provides a greater than expected improvement in the condition of subjects suffering from a neurodegenerative with an associated cognitive deficit, such as Alzheimer's Disease or Parkinson's disease, or from a cognitive deficit which may arise from a normal process such as aging or from an abnormal process such as injury, than would be expected from administration of the active ingredients alone. Further, the combination allows for a lower overall dose of each of the active ingredients to be administered thus reducing side effects and decreasing any reduction in the effectiveness of each of the active ingredients over time. Acetylcholinesterase inhibitors which may be used include any which are known to the skilled person. Examples are physostigmine, neostigmine, edrophonium and its chloride, pyridostigmine and its bromide, eptastigmine.and its tartrate, galanthamine and its hydrochloride and hydrobromide, metrifonate, tacrine and its hydrochloride, eseridine and its salicylate, suronacrine and its maleate, velnacrine and its maleate, amiridine and its hydrochloride, 7- methoxy tacrine, SM-10888 and its citrate, phenserine and its tartrate, ENA-713, donepezil and its hydrochloride, TAK-147, CP-118954, huperzine A and zifrosilone.
Any inverse agonist of the GABAA as receptor subtype may be used which fulfills the criteria of WO-A-9625948. The inverse agonist may be either binding selective for the 0:5 subtype or functionally selective, or both. Thus the inverse agonist is preferably an antagonist, or has insignificant agonist or inverse agonist properties at the other GABAA receptor subtypes when measured in oocytes as described in WO-A-9625948.
Thus the inverse agonist preferably has a functional efficacy at the g receptor subunit of less than -20% and functional efficacies at the αi, α.2, and 0:3 receptor subunits of between -20 and +20%. By functional efficacy is meant the percentage modulation of the EC20 response produced by GABA, upon coadministration of the inverse agonist, in oocytes expressing GABAA receptor channels containing the α receptor subunit under test. Details of this measurement are given in WO-A-9625948.
The inverse agonist preferably binds selectively to GABAA receptors containing the as subunit 10, 25 and particularly 50 times compared to GABAA receptors subunits containing the αi, 0:2 or 0:3 subunits. Preferably this binding selectivity is shown over all these subunits.
A preferred class of inverse agonists, which are disclosed in WO-A-9850385, are of formula I:
Figure imgf000005_0001
wherein:
R1 is hydrogen, halogen or CN or a group Cι-4alkyl, C2-4alkenyl, C2-4alkynyl, Ci. alkoxy, C2-4alkenyloxy or C2-4alkynyloxy, each of which groups is unsubstituted or substituted with one or two halogen atoms or with a pyridyl or phenyl ring each of which rings may be unsubstituted or independently substituted by one or two halogen atoms or nitro, cyano, amino, methyl or CF3 groups; R2 is hydrogen, halogen or CN or a group Cι-4alkyl, C2-4alkenyl,
C2-4alkynyl, Cι-4alkoxy, C2-4alkenyloxy or C2-4alkynyloxy each of which groups is unsubstituted or substituted with one or two halogen atoms;
L is 0, S or NRn where Rn is H, Cj-βalkyl or C3-6cycloalkyl;
X is a 5-membered heteroaromatic ring containing 1, 2, 3 or 4 heteroatoms independently chosen from oxygen, nitrogen and sulphur, at most one of the heteroatoms being oxygen or sulphur, or a 6-membered heteroaromatic ring containing 1, 2 or 3 nitrogen atoms, the 5- or 6-membered heteroaromatic ring being optionally fused to a benzene ring and the heteroaromatic ring being optionally substituted by Rx and/or R ' and/or R*, where Rx is halogen, R3, OR*, OCOR3, NR R5, NR COR5, tri(C1-6alkyl)silylC1-6alkoxyC1- alkyl) CN or R9, is halogen, R3, OR3, OCOR3, NR4R5, NR4COR5 or CN and R* is R3, OR3 or OCOR3, where R3 is Ci-Galkyl, C2-6alkenyl, C2-ealkynyl, C3-6cycloalkyl, hydroxyCi-calkyl and R3 is optionally mono, di- or tri-fluorinated, R4 and Rs are each independently hydrogen, Ci-calkyl, C2-Galkenyl, C2-Galkynyl, C3-βcycloalkyl or CF3 or R4 and R5, together with the nitrogen atom to which they are attached, form a 4-7 membered heteroaliphatic ring containing the nitrogen atom as the sole heteroatom, and R9 is benzyl or an aromatic ring containing either 6 atoms, 1, 2 or 3 of which are optionally nitrogen, or 5 atoms, 1, 2 or 3 of which are independently chosen from oxygen, nitrogen and sulphur, at most one of the atoms being oxygen or sulphur, and R9 is optionally substituted by one, two or three substituents independently chosen from halogen atoms and Cι-4alkyl, C2-4alkenyl, C2-4alkynyl,
Figure imgf000006_0001
C2-4alkenyloxy and C2-4alkynyloxy groups each of which groups is unsubstituted or substituted by one, two or three halogen atoms, and when X is a pyridine derivative, the pyridine derivative is optionally in the form of the N-oxide and providing that when X is a tetrazole derivative it is protected by a Cι-4alkyl group; or X is phenyl optionally substituted by one, two or three groups independently selected from halogen, cyano, Ci- ealkyl, C2-Galkenyl, C2-6alkynyl and Cs ccycloalkyl;
Y is optionally branched Cj.4alkylidene optionally substituted by an oxo group or Y is a group (CH2)jO wherein the oxygen atom is nearest the group X and j is 2, 3 or 4;
Z is a 5-membered heteroaromatic ring containing 1, 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulphur, at most one of the heteroatoms being oxygen or sulphur and providing that when two of the heteroatoms are nitrogen an oxygen or sulphur atom is also present and that when one of the atoms is oxygen or sulphur then at least one nitrogen atom is present, or a 6-membered heteroaromatic ring containing 2 or 3 nitrogen atoms, Z being optionally substituted by Rv and/or Rw, where Rv is halogen, RG, NR7R8, NR7COR8, CN, furyl, thienyl, phenyl, benzyl, pyridyl or a 5-membered heteroaromatic ring containing at least one nitrogen atom and optionally 1, 2 or 3 other heteroatoms independently selected from oxygen, nitrogen and sulphur, at most one of the other heteroatoms being oxygen or sulphur and Rw is R6 or CN;
RG is Ci-βalkyl, C2-6alkenyl, C2-6alkynyl, C3-Gcycloalkyl, hydroxyd-calkyl, Ci-calkoxy, C2 c,alkenyloxy, C2-6alkynyloxy, CH2F or CF3; and R7 and R8 are each independently hydrogen, Ci-ealkyl, C2-Galkenyl, C2-6alkynyl, C3-Gcycloalkyl or CF3 or R7 and R8, together with the nitrogen atom to which they are attached, form a 4-7 membered heteroaliphatic ring containing the nitrogen atom as the sole heteroatom; or a pharmaceutically acceptable salt thereof.
As used herein, the expression "d-Galkyl" includes methyl and ethyl groups, and straight-chained and branched propyl, butyl, pentyl and hexyl groups. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and t-butyl. Derived expressions such as
Figure imgf000007_0001
"C2-4alkenyl", "C2-6alkeny_", "hydroxyCi-calkyl", "C2-4alkyl" and "C2.6alkyny_" are to be construed in an analogous manner.
The expression "C3-Gcycloalkyl" as used herein includes cyclic propyl, butyl, pentyl and hexyl groups such as cyclopropyl and cyclohexyl.
Suitable 5- and 6-membered heteroaromatic rings include pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, oxadiazolyl and thiadiazolyl groups. A suitable 5-membered heteroaromatic ring containing four nitrogen atoms is tetrazolyl. Suitable 6-membered heteroaromatic rings containing three nitrogen atoms include 1,2,4-triazine and 1,3,5-triazine. The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, of which fluorine and chlorine are preferred.
As used herein the term "Ci-βalkoxy" includes methoxy and ethoxy groups, and straight-chained, branched and cyclic propoxy, butoxy, pentoxy and hexoxy groups, including cyclopropylmethoxy. Derived expressions such as "C2-6alkenyloxy", "C2-6alkynyloxy", "C1-4alkoxy",
"C2-4alkenyloxy" and "C2-4alkyloxy" should be construed in an analogous manner.
Four particular compounds which can be used are: 6-(l-methylimidazol-4-yl)methyloxy-3-(5-methylisoxazol-3-yl)-l,2,4- triazolo[3,4-a]phthalazine; 3-(5-methylisoxazol-3-yl)-6-(l-methyl- 1,2, 3-triazol-4-yl)methyloxy- 1,2,4- triazolo [3 , 4- a] phthalazine ;
3- (5-methylisoxazol- 3-yl)-6- (2-pyridyl)- 1 , 2, 4-triazolo [3, 4-a]phthalazine ; and 3-(5-methylisoxazol-3-yl)-6-(l-methylimidazol-4-yl)-l,2,4-triazol-3- y lmethyloxy- 1 , 2, 4-triazolo [3 , 4- a]phthalazine . The second of the above compounds is particularly favoured.
The present invention also provides a pharmaceutical composition comprising an acetylcholinesterase inhibitor, an inverse agonist of the GABAA 0.5 receptor subtype and a pharmaceutically acceptable carrier. There is also provided a kit of parts comprising a first pharmaceutical composition comprising an acetylcholinesterase inhibitor and a first pharmaceutically acceptable carrier and a second pharmaceutical composition comprising an inverse agonist of the GABAA 0.5 receptor subtype and a second pharmaceutically acceptable carrier for simultaneous, sequential or separate administration.
There is further provided a combination of an acetylcholinesterase inhibitor and an inverse agonist of the GABAA 0.5 receptor subtype for use in a method of treatment of the human body, particularly for the treatment of a neurodegenerative disorder with associated cognitive deficit such as Alzheimer's Disease or Parkinson's disease, or of a cognitive deficit arising from a normal process such as aging or of an abnormal process such as injury. The combination is particularly beneficial in the treatment of Alzheimer's Disease. There is also provided the use of a combination of an acetylcholinesterase inhibitor and an inverse agonist of the GABAA s receptor subtype in the manufacture of a medicament for the treatment of a neurodegenerative disorder such as Alzheimer's Disease or Parkinson's disease, or of a cognitive deficit arising from a normal process such as aging or of an abnormal process such as injury. The treatment of Alzheimer's Disease is particularly preferred. There is also disclosed a method of treatment of a subject suffering from a neurodegenerative disorder, such as Alzheimer's Disease or Parkinson's disease, or a cognitive deficit arising from a normal process such as aging or an abnormal process such as injury, which comprises administering to that subject a therapeutically effective amount of a combination of an acetylcholinesterase inhibitor and an inverse agonist of the GABAA 0.5 receptor subtype. The treatment of Alzheimer's Disease is particularly preferred.
The pharmaceutical compositions of the present invention are preferably in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, transdermal patches, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums or surfactants such as sorbitan monooleate, polyethylene glycol, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of each active ingredient of the present invention. Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of each active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin. For the treatment of a neurodegenerative condition, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.01 to 100 mg/kg per day, and especially about 0.01 to 5 mg/kg of body weight per day of each active ingredient. The compounds may be administered on a regimen of 1 to 4 times per day. In some cases, however, dosage outside these limits may be used.
The synergistic effect of the combination of the present invention can be shown, for example, by comparing the combined dosage of the combination with dosages of the same amount of each of the active ingredients separately on subjects using the Mini-Mental State Examination (MMSE) as described in Folstein and Folstein J. Psychiat. Res., 1975, 12, 189-198 or a variant thereof as discussed in Tombaugh and Mclntyre, JAGS, 1992, 40, 922-935.

Claims

1. A combination of an acetylcholinesterase inhibitor and an inverse agonist of the GABAA O 5 receptor subtype for separate, sequential or simultaneous aministration.
2. A combination according to claim 1 wherein the inverse agonist has a functional efficacy at the as receptor subtype of less than 20%, and a functional efficacy at the ╬▒i, 0.2 and 0.3 receptor subtypes of between -20 and +20 %.
3. A combination according to claim 1 or 2 wherein the inverse agonist has a binding ration of greater than 10:1 to GABAA receptors containing the as receptor subtype compared to GABAA receptors containing the ╬▒1; 0:2 or cc3 subtypes.
4. A combination according to claim 1 wherein the inverse agonist is 3-(5-methylisoxazol-3-yl)-6-(l-methyl-l,2,3-triazol-4-yl)methyloxy-l,2,4- _riazolo[3,4-a]phthalazine.
5. A combination according to any one of the preceding claims wherein the acetylcholinesterase inhibitor is selected from physostigmine bromide, eptastigmine and its tartrate, galanthamine and its hydrochloride and hydrobromide, metrifonate, tacrine and its hydrochloride, eseridine and its salicylate, suronacrine and its maleate, velnacrine and its maleate, amiridine and its hydrochloride, 7-methoxytacrine, SM-10888 and its citrate, phenserine and its tartrate, ENA-713, donepezil and its hydrochloride, TAK-147, CP-118954, huperzine A and zifrosilone.
6. A pharmaceutical composition comprising a combination as defined if any one of claims 1 to 5 and a pharmaceutically acceptable carrier for simultaneous administration.
7. A kit of parts comprising a first pharmaceutical composition comprising an acetylcholinesterase inhibitor and a first pharmaceutically acceptable carrier and a second pharmaceutical composition comprising an inverse agonist of the GABAA cts receptor subtype and a second pharmaceutically acceptable carrier for simultaneous, separate or sequential administration.
8. A method of treatment of a subject suffering from a neurodegenerative disorder or a cognitive deficit comprising administering to that subject a therapeutically effective amount of a combination of an acetylcholinesterase inhibitor and an inverse agonist of the GABAA 5 receptor subtype.
PCT/GB1999/000778 1998-03-16 1999-03-16 Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor WO1999047131A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000536371A JP2002506815A (en) 1998-03-16 1999-03-16 Combination of GABAAα5 inverse agonist and acetylcholinesterase inhibitor
AU28464/99A AU753077B2 (en) 1998-03-16 1999-03-16 Combination of a GABA-A alpha 5 inverse agonist and an acetylcholinesterase inhibitor
EP99909095A EP1061952A2 (en) 1998-03-16 1999-03-16 Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
CA002323618A CA2323618A1 (en) 1998-03-16 1999-03-16 Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9805561.9 1998-03-16
GBGB9805561.9A GB9805561D0 (en) 1998-03-16 1998-03-16 A combination of therapeutic agents

Publications (2)

Publication Number Publication Date
WO1999047131A2 true WO1999047131A2 (en) 1999-09-23
WO1999047131A3 WO1999047131A3 (en) 1999-11-04

Family

ID=10828631

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000778 WO1999047131A2 (en) 1998-03-16 1999-03-16 Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor

Country Status (6)

Country Link
EP (1) EP1061952A2 (en)
JP (1) JP2002506815A (en)
AU (1) AU753077B2 (en)
CA (1) CA2323618A1 (en)
GB (1) GB9805561D0 (en)
WO (1) WO1999047131A2 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
WO2002032412A2 (en) * 2000-10-17 2002-04-25 Pfizer Products Inc. Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6723332B2 (en) 2000-05-26 2004-04-20 Neurogen Corporation Oxomidazopyridine-carboxamides
US6828329B2 (en) 2000-06-26 2004-12-07 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
WO2005027975A1 (en) * 2003-09-22 2005-03-31 Pfizer Limited Combinations of alpha-2-delta ligands and acetylcholinesterase inhibitors
US6936617B2 (en) 2001-07-13 2005-08-30 Neurogen Corporation Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands
WO2005112946A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011100373A1 (en) 2010-02-09 2011-08-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10159648B2 (en) 2015-05-22 2018-12-25 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2511599A1 (en) * 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
KR101743960B1 (en) * 2015-07-06 2017-06-08 서울대학교산학협력단 G 19 Pharmaceutical composition for preventing treating or retarding Alzheimers disease or dementia comprising G protein-Coupled Receptor19 agonist as an active ingredient

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647580A (en) * 1985-07-18 1987-03-03 Syntex (U.S.A.) Inc. Treatment of Alzheimer's disease
WO1996025948A1 (en) * 1995-02-23 1996-08-29 Merck Sharp & Dohme Limited PREPARATION AND USE OF A SPECIFIC GABA-Aα5 RECEPTOR LIGAND FOR TREATMENT OF ALZHEIMER'S DISEASE
WO1998004560A1 (en) * 1996-07-25 1998-02-05 Merck Sharp & Dohme Limited SUBSTITUTED TRIAZOLO PYRIDAZINE DERIVATIVES AS INVERSE AGONISTS OF THE GABAAα5 RECEPTOR SUBTYPE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647580A (en) * 1985-07-18 1987-03-03 Syntex (U.S.A.) Inc. Treatment of Alzheimer's disease
WO1996025948A1 (en) * 1995-02-23 1996-08-29 Merck Sharp & Dohme Limited PREPARATION AND USE OF A SPECIFIC GABA-Aα5 RECEPTOR LIGAND FOR TREATMENT OF ALZHEIMER'S DISEASE
WO1998004560A1 (en) * 1996-07-25 1998-02-05 Merck Sharp & Dohme Limited SUBSTITUTED TRIAZOLO PYRIDAZINE DERIVATIVES AS INVERSE AGONISTS OF THE GABAAα5 RECEPTOR SUBTYPE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROSENBERG D R ET AL: "COGNITIVE ENHANCING AGENTS FOR THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER'S TYPE" DRUGS OF TODAY / MEDICAMENTOS DE ACTUALIDAD, vol. 26, no. 7, 1 October 1990 (1990-10-01), pages 449-471, XP000616601 ISSN: 0025-7656 *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
US6972293B2 (en) 1999-04-02 2005-12-06 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6583169B2 (en) 1999-04-02 2003-06-24 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6723332B2 (en) 2000-05-26 2004-04-20 Neurogen Corporation Oxomidazopyridine-carboxamides
US6828329B2 (en) 2000-06-26 2004-12-07 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
WO2002032412A3 (en) * 2000-10-17 2003-03-20 Pfizer Prod Inc Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders
WO2002032412A2 (en) * 2000-10-17 2002-04-25 Pfizer Products Inc. Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders
AU2001294117B2 (en) * 2000-10-17 2006-07-27 Neurogen Corporation Combination use of acetylcholinesterase inhibitors and GABAA inverse agonists for the treatment of cognitive disorders
US6936617B2 (en) 2001-07-13 2005-08-30 Neurogen Corporation Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands
WO2005027975A1 (en) * 2003-09-22 2005-03-31 Pfizer Limited Combinations of alpha-2-delta ligands and acetylcholinesterase inhibitors
WO2005112946A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2481408A2 (en) 2007-03-01 2012-08-01 Probiodrug AG New use of glutaminyl cyclase inhibitors
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011100373A1 (en) 2010-02-09 2011-08-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10624875B2 (en) 2012-11-14 2020-04-21 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
US10159648B2 (en) 2015-05-22 2018-12-25 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase

Also Published As

Publication number Publication date
AU753077B2 (en) 2002-10-10
GB9805561D0 (en) 1998-05-13
CA2323618A1 (en) 1999-09-23
EP1061952A2 (en) 2000-12-27
JP2002506815A (en) 2002-03-05
WO1999047131A3 (en) 1999-11-04
AU2846499A (en) 1999-10-11

Similar Documents

Publication Publication Date Title
AU753077B2 (en) Combination of a GABA-A alpha 5 inverse agonist and an acetylcholinesterase inhibitor
CA2542442C (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
EP0216555B1 (en) Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections
JPH06507621A (en) Improvement in treatment with benzodiazepines
WO2001013909A2 (en) Compositions and methods for treating opiate intolerance
US6455552B1 (en) Combination of a GABAA α5 inverse agonist and a muscarinic agonist
AU752013B2 (en) Combination of a GABA-A alpha 5 inverse agonist and a nicotinic agonist
US6090829A (en) Method for treating excessive aggression
US20060079513A1 (en) Methods and compositions including methscopolamine nitrate
KR960005145B1 (en) Pharmaceutical composition for use against hypertension and congestive heart failure
CZ27299A3 (en) Method of treating bipolar affect disorder
US20040001895A1 (en) Combination treatment for depression and anxiety
CA2261676A1 (en) Method for treating excessive aggression
AU2014200818A1 (en) Kit, composition, product or medicament for treating cognitive impairment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1999909095

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09622954

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 28464/99

Country of ref document: AU

ENP Entry into the national phase in:

Ref document number: 2323618

Country of ref document: CA

Ref country code: CA

Ref document number: 2323618

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase in:

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999909095

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 28464/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999909095

Country of ref document: EP